Carl Petersson works at Merck KgaA in Darmstadt, Germany, as a scientific director, drug disposition. In this position he is offering strategic, educational, and hands-on support to optimize and predict human ADME properties of small molecules. In addition, he is serving on several multidisciplinary drug discovery teams, in which he is responsible for the pharmacokinetic and drug metabolism contributions. Before joining his current company, he has worked 12 years at the CNS & Pain unit of AstraZeneca in similar roles. Dr. Petersson has a Ph.D. in Organic Chemistry obtained at the Swedish University of Agricultural Sciences and did his postdoctoral research at the University of Alberta, Edmonton, Canada.